Drug Repurposing for Epstein-Barr Virus Associated Tumors

A new study published in the peer-reviewed OMICS: A Journal of Integrative Biology identified differentially expressed host and viral microRNAs (miRNAs) in six Epstein-Barr virus (EBV) associated tumors. The study reports several drug candidates for repurposing and targeting EBV latent infection: Glyburide, Levodopa, Nateglinide, and Stiripentol, among others. Click here to read the article now.

The authors, Anamika Thakur and Manoj Kumar, PhD, from the Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India, note: “This is the first integrative analysis, to the best of our knowledge, in regard to the potential therapeutic targets and drug repurposing candidates against the EBV tumors.” EBV is associated with several types of malignancies, such as gastric carcinoma, Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin’s lymphoma.

“Epstein-Barr virus is a major planetary health burden especially in the oncology clinic. The study makes a contribution toward antiviral drug innovation for treatment of EBV infection and prevention of EBV-related tumors,” says Vural Özdemir, MD, PhD, DABCP, Editor-in-Chief of OMICS.

About the Journal

OMICS: A Journal of Integrative Biology is an authoritative and highly innovative peer-reviewed interdisciplinary journal published monthly online, addressing the latest advances at the intersection of postgenomics medicine, biotechnology and global society, including the integration of multi-omics knowledge, data analyses and modeling, and applications of high-throughput approaches to study complex biological and societal problems. Public policy, governance and societal aspects of the large-scale biology and 21st century data-enabled sciences are also peer-reviewed. Complete tables of content and a sample issue may be viewed on the OMICS: A Journal of Integrative Biology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 90 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.